$AMTX

Aemetis Shows Operating Inflection in Q2 2026, Says Stonegate Capital Partners

Stonegate Capital Partners updated on Aemetis Inc. (NASDAQ: AMTX), saying Q2 2026 showed an operating inflection. Aemetis reported revenue of $62.7M, below consensus $68.6M, but gross profit rose to $13.5M and adjusted EBITDA to $9.7M. Dairy RNG volume rose 38% to 146,900 MMBtu; Stonegate cites 45Z credits and LCFS pathway progress, while noting balance sheet refinancing remains a key constraint.

Original reporting
Published Aug 10, 2026, 4:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aemetis Shows Operating Inflection in Q2 2026, Says Stonegate Capital Partners — source image
Decision brief

The 30-second read

$AMTXNeutralMed
01

Why it matters

The update provides concrete operating KPIs (gross profit swing, adjusted EBITDA improvement, RNG volume growth, LCFS pathway count, and planned MVR commissioning) while reiterating liquidity constraints (unrestricted cash and total debt) as the key gating factor for equity value.

02

Market read

Traders may reprice AMTX based on improved operating trajectory, but the dominant near-term variable is refinancing progress and the timing of additional production catalysts in 2026.

03

What to watch

The revenue miss is attributed to India tender timing; traders may discount the durability of the improvement until tender timing normalizes and refinancing milestones are confirmed.

Relevance 6/10Novelty 5/10Timing: post-Q2 2026 update, investors watching refinancing milestones and Q3 2026 digester commissioning

Background

Stonegate Capital Partners issued an update framing Aemetis’ Q2 2026 results as an operating inflection, emphasizing renewable-fuels margin drivers and tax-credit recognition.

Company-level read

Ticker impact

$AMTXNeutralMedium confidence
Context

Stonegate says Aemetis’ Q2 2026 operating inflection is visible via improved margins, RNG output, and 45Z tax-credit recognition despite a revenue miss.

Expected impact

Near-term trading likely follows refinancing expectations rather than operating progress alone.

Evidence & confidence

The article provides quantified operating improvements (gross profit, adjusted EBITDA, RNG volume, LCFS pathways) but flags unrestricted cash of $1.0M and total debt of $415.9M as the binding constraint.

Market effects

Highlights how LCFS pathway approvals, RNG production, and 45Z credits can swing renewable-fuels economics, but liquidity remains a key risk factor for the group.

Limited direct regional spillover; focus is on California renewable fuels and RNG operations.

Modest, as the India tender timing issue points to cross-border demand timing rather than a global structural shift.

Counterpoint

Operating inflection may not translate into free cash flow if refinancing is delayed or terms worsen, making the equity risk primarily balance-sheet driven.

Key entities

  • Aemetis Inc.

    NASDAQ-listed renewable fuels and RNG producer discussed as showing operating inflection in Q2 2026, with refinancing risk highlighted.

  • Stonegate Capital Partners

    Dallas-based firm issuing the update and framing the operating and balance-sheet implications.

Related articles

$AMTXMedAI 8/10

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) reported Q2 2026 revenue of $62.7M, up 20% YoY, with operating income of $5.8M, reversing a prior-year loss. Growth was driven by ethanol and renewable natural gas segments. Adjusted EBITDA improved to $9.7M from -$5.8M. Management highlighted projects like mechanical vapor recompression and LCFS pathway approvals, but noted risks from uncertain emissions rates and feedstock constraints.

$AMTXMed

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) Q2 2026 earnings call said consolidated revenue rose 20% year over year, operating income improved by $16.4 million, and adjusted EBITDA increased by $15.5 million versus Q2 2025. The company cited CARB approval of 7 LCFS pathways and pending approvals for 6 digesters, plus ethanol projects including a $32 million annual cash flow MVR system. India biodiesel revenue was $2.5 million, with expected $17 million from new allocations.

$AMTXMed

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.

$AMTXMed

AEMETIS, INC (AMTX): Results of Operations and Financial Condition

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemetis.com Aemetis Reports Second Quarter 2026 Financial Results Revenue Growth o

$AMTXMed

Aemetis stock rises on India biodiesel supply deal

Aemetis Inc (NASDAQ:AMTX) shares rose 4.3% after its India unit, Universal Biofuels, secured about $17 million in biodiesel supply contracts. Over three months it will deliver more than 18 million liters to India’s three government-owned Oil Marketing Companies, supporting a policy to raise biodiesel blending to 5% by 2030. Additional orders are expected through 2026.